Number of MRI T1-hypointensity corrected by T2/FLAIR lesion volume indicates clinical severity in patients with multiple sclerosis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
11
2019
accepted:
18
03
2020
entrez:
4
4
2020
pubmed:
4
4
2020
medline:
15
7
2020
Statut:
epublish
Résumé
Progressive brain atrophy, development of T1-hypointense areas, and T2-fluid-attenuated inversion recovery (FLAIR)-hyperintense lesion formation in multiple sclerosis (MS) are popular volumetric data that are often utilized as clinical outcomes. However, the exact clinical interpretation of these volumetric data has not yet been fully established. We enrolled 42 consecutive patients with MS who fulfilled the revised McDonald criteria of 2010. They were followed-up for more than 3 years from onset, and cross-sectional brain volumetry was performed. Patients with no brain lesions were excluded in advance from this study. For the brain volumetric data, we evaluated several parameters including age-adjusted gray-matter volume atrophy, age-adjusted white-matter volume atrophy, and T2-FLAIR lesion volume. The numbers of T1-hypointense and T2-FLAIR-hyperintense areas were also measured along the same timeline. The clinical data pertaining to disease duration, expanded disability status scale (EDSS), and MS severity score (MSSS) at the timing of volumetry were collected. Among the 42 patients with MS and brain lesions, the number of T1-hypointensity (rho = 0.51, p<0.001), gray-matter atrophy (rho = 0.40, p<0.01) and white-matter atrophy (rho = 0.49, p<0.001) correlated with the EDSS. T1-hypointensity count divided by FLAIR lesion volume correlated with the MSSS (rho = 0.60, p<0.001). Meanwhile, counts or volumes of FLAIR-hyperintense lesions were associated only with the times of past relapses, and did not correlate with present neurological disability level or ongoing disease activity. These findings were consistent regardless of the presence of spinal cord lesions. Numbers of T1-hypointensities and brain atrophy equally indicated the current neurological disability in MS. The number of T1-hypointensities divided by FLAIR lesion volume represented the clinical severity. The size or number of FLAIR lesions reflected earlier relapses but was not a good indicator of neurological disability or clinical severity.
Identifiants
pubmed: 32243459
doi: 10.1371/journal.pone.0231225
pii: PONE-D-19-32222
pmc: PMC7122737
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0231225Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cell J. 2017 Apr-Jun;19(1):1-10
pubmed: 28367411
Mult Scler. 2013 Feb;19(2):162-6
pubmed: 22740437
Mult Scler Int. 2014;2014:609694
pubmed: 24587905
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Ann Neurol. 2014 Aug;76(2):305-9
pubmed: 24977390
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
J Neurol Neurosurg Psychiatry. 2011 Jan;82(1):72-7
pubmed: 20627965
P T. 2012 Mar;37(3):175-84
pubmed: 22605909
PeerJ. 2016 Mar 15;4:e1797
pubmed: 27014514
Brain. 1997 Nov;120 ( Pt 11):2059-69
pubmed: 9397021
Mult Scler Relat Disord. 2017 May;14:35-45
pubmed: 28619429
J Clin Neurol. 2018 Jul;14(3):387-392
pubmed: 29971979
Eur J Neurol. 2019 Jan;26(1):27-40
pubmed: 30300457
Brain. 2003 Aug;126(Pt 8):1782-9
pubmed: 12821527
Neurology. 2017 Jan 24;88(4):403-413
pubmed: 27986875
Neurology. 1995 Sep;45(9):1684-90
pubmed: 7675227
Mult Scler. 2005 Oct;11(5):524-31
pubmed: 16193889
Mult Scler. 2014 Mar;20(3):365-73
pubmed: 23836878
Mult Scler. 2008 Jul;14(6):764-9
pubmed: 18611989
PLoS One. 2017 May 15;12(5):e0177727
pubmed: 28505177
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Lancet Neurol. 2016 Mar;15(3):292-303
pubmed: 26822746
Tohoku J Exp Med. 2006 Dec;210(4):307-13
pubmed: 17146196
Adv Clin Exp Med. 2019 Jul;28(7):989-999
pubmed: 30729761
Neurol Sci. 2010 Nov;31(Suppl 2):S245-8
pubmed: 20635111
J Neuroimmunol. 2017 May 15;306:68-75
pubmed: 28385190
Brain Behav. 2015 Sep;5(9):e00362
pubmed: 26445701
Neural Regen Res. 2019 Mar;14(3):373-386
pubmed: 30539801
Neurology. 2005 Apr 12;64(7):1144-51
pubmed: 15824338
Neurol Ther. 2018 Jun;7(1):59-85
pubmed: 29243029
N Engl J Med. 2000 Sep 28;343(13):938-52
pubmed: 11006371
Front Neurol. 2017 Sep 04;8:433
pubmed: 28928705
J Neurol. 2020 Feb;267(2):395-405
pubmed: 31654116
Neurology. 2006 Mar 14;66(5):685-92
pubmed: 16534104
Ther Adv Neurol Disord. 2012 Jan;5(1):13-22
pubmed: 22276073
Nat Rev Neurol. 2010 Dec;6(12):648-9
pubmed: 21131911
Neurology. 1996 Dec;47(6):1469-76
pubmed: 8960729
Ann Neurol. 2018 Feb;83(2):210-222
pubmed: 29331092